These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29634818)

  • 1. Sequencing of Tumor DNA to Guide Cancer Risk Assessment and Therapy.
    Spencer DH; Ley TJ
    JAMA; 2018 Apr; 319(14):1497-1498. PubMed ID: 29634818
    [No Abstract]   [Full Text] [Related]  

  • 2. [Critical parameters in clinical sequencing].
    Jordan B
    Med Sci (Paris); 2012 Jan; 28(1):109-11. PubMed ID: 22289839
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicine. Personalized cancer diagnostics.
    Corless CL
    Science; 2011 Dec; 334(6060):1217-8. PubMed ID: 22144608
    [No Abstract]   [Full Text] [Related]  

  • 4. The mutREAD method detects mutational signatures from low quantities of cancer DNA.
    Perner J; Abbas S; Nowicki-Osuch K; Devonshire G; Eldridge MD; Tavaré S; Fitzgerald RC
    Nat Commun; 2020 Jun; 11(1):3166. PubMed ID: 32576827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A practical guide to cancer subclonal reconstruction from DNA sequencing.
    Tarabichi M; Salcedo A; Deshwar AG; Ni Leathlobhair M; Wintersinger J; Wedge DC; Van Loo P; Morris QD; Boutros PC
    Nat Methods; 2021 Feb; 18(2):144-155. PubMed ID: 33398189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms underlying mutational signatures in human cancers.
    Helleday T; Eshtad S; Nik-Zainal S
    Nat Rev Genet; 2014 Sep; 15(9):585-98. PubMed ID: 24981601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of oncogenes and tumor suppressor genes in human cancer using denaturing gradient gel electrophoresis.
    Guldberg P; Grønbaek K; Worm J; thor Straten P; Zeuthen J
    Methods Mol Med; 2002; 68():125-39. PubMed ID: 11901498
    [No Abstract]   [Full Text] [Related]  

  • 8. Next-generation DNA sequencing: implications for oncology care.
    Mahon SM
    Oncol Nurs Forum; 2013 Sep; 40(5):437-9. PubMed ID: 23989017
    [No Abstract]   [Full Text] [Related]  

  • 9. Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.
    Shu Y; Wu X; Tong X; Wang X; Chang Z; Mao Y; Chen X; Sun J; Wang Z; Hong Z; Zhu L; Zhu C; Chen J; Liang Y; Shao H; Shao YW
    Sci Rep; 2017 Apr; 7(1):583. PubMed ID: 28373672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor sequencing takes off, but insurance reimbursement lags.
    Chakradhar S
    Nat Med; 2014 Nov; 20(11):1220-1. PubMed ID: 25375911
    [No Abstract]   [Full Text] [Related]  

  • 11. [The bewildering complexity of cancer].
    Jordan B
    Med Sci (Paris); 2011; 27(8-9):781-6. PubMed ID: 21880268
    [No Abstract]   [Full Text] [Related]  

  • 12. p53--master and commander.
    Foulkes WD
    N Engl J Med; 2007 Dec; 357(25):2539-41. PubMed ID: 18094374
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation sequencing applications in cancer research.
    Zhang W; Nykter M; Chen K
    Cancer Lett; 2013 Nov; 340(2):149-50. PubMed ID: 23764479
    [No Abstract]   [Full Text] [Related]  

  • 15. More Pitfalls Related to Next-generation Sequencing (NGS).
    Sorscher S
    Am J Clin Oncol; 2016 Aug; 39(4):424. PubMed ID: 27465427
    [No Abstract]   [Full Text] [Related]  

  • 16. Realizing the opportunities of genomics in health care.
    Ginsburg GS
    JAMA; 2013 Apr; 309(14):1463-4. PubMed ID: 23571581
    [No Abstract]   [Full Text] [Related]  

  • 17. Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices.
    Mariani S; Bertero L; Coppola V; Saracco G; Arezzo A; Francia Di Celle P; Metovic J; Marchiò C; Cassoni P
    Expert Rev Mol Diagn; 2018 May; 18(5):467-475. PubMed ID: 29676606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutation detection by SSCP and sequencing.
    Hakkarainen J; Welsh JA; Vähäkangas KH
    Methods Mol Med; 2004; 97():191-208. PubMed ID: 15064494
    [No Abstract]   [Full Text] [Related]  

  • 19. Next-generation sequencing for the general cancer patient.
    Avila M; Meric-Bernstam F
    Clin Adv Hematol Oncol; 2019 Aug; 17(8):447-454. PubMed ID: 31449513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutation detection efficiency in EGFR: a comparison between high resolution melting analysis and Sanger sequencing.
    Joy RA; Thelakkattusserry SK; Vikkath N; Bhaskaran R; Krishnan S; Vasudevan D; Ariyannur PS
    BMC Cancer; 2020 Sep; 20(1):902. PubMed ID: 32962681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.